Ionis Pharmaceuticals, Inc.: Diabetes Mellitus, Type 2 trials
The registry lists 15 Diabetes Mellitus, Type 2 studies with Ionis Pharmaceuticals, Inc. as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 3Phase 2 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedNCT03371355Phase 2Results posted
- Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 DiabetesCompletedNCT03334214Phase 2Results posted
- Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 DiabetesCompletedNCT02824003Phase 2
- Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 DiabetesCompletedNCT02583919Phase 2
- Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 DiabetesCompletedNCT01968265Phase 2
- Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 DiabetesCompletedNCT01918865Phase 2
- Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 DiabetesCompletedNCT01885260Phase 2
- Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 DiabetesTerminatedNCT01647308Phase 2
- Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy VolunteersCompletedNCT00836225Phase 1
- Safety Study of ISIS 325568 in Healthy VolunteersCompletedNCT00519727Phase 1
- Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With SulfonylureaCompletedNCT00455598Phase 2
- Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715CompletedNCT00365781Phase 1
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior TreatmentCompletedNCT00330330Phase 2
- Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 DiabeticsTerminatedNCT00330200Phase 2
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With SulfonylureaWithdrawnNCT00327626Phase 2